MetLife, Inc. (NYSE: MET) today announced its full year and
fourth quarter 2024 results.
Full Year Results Summary
- Net income of $4.2 billion, compared to net income of $1.4
billion for the full year 2023. Net income of $5.94 per share, up
228 percent from the prior year.
- Adjusted earnings of $5.8 billion, compared to adjusted
earnings of $5.5 billion for the full year 2023. Adjusted earnings
of $8.15 per share, up 12 percent from the prior year.
- Adjusted earnings, excluding total notable items, of $5.8
billion, compared to $5.6 billion for the full year 2023. On a per
share basis, adjusted earnings, excluding total notable items, of
$8.11, up 11 percent from $7.33 for the full year 2023.
- Book value of $34.28 per share, down 4 percent from $35.85 per
share at December 31, 2023.
- Adjusted book value* of $54.81 per share, up 2 percent from
$53.75 per share at December 31, 2023.
- Return on equity (ROE) of 16.9 percent.
- Adjusted ROE* of 15.2 percent.
- Holding company cash and liquid assets of $5.1 billion at
December 31, 2024, which is above the target cash buffer of $3.0 -
$4.0 billion.
Fourth Quarter Results Summary
- Net income of $1.2 billion, or $1.78 per share, compared to net
income of $574 million, or $0.77 per share, in the fourth quarter
of 2023.
- Adjusted earnings of $1.5 billion, or $2.09 per share, compared
to adjusted earnings of $1.4 billion, or $1.83 per share, in the
fourth quarter of 2023.
- Adjusted earnings, excluding total notable items, of $1.4
billion, or $2.08 per share, compared to adjusted earnings,
excluding total notable items, of $1.4 billion, or $1.93 per share,
in the fourth quarter of 2023.
- ROE of 19.6 percent.
- Adjusted ROE* of 15.4 percent; adjusted ROE,* excluding notable
items, of 15.3 percent.
"MetLife's strength and resilience were evident in 2024 as we
delivered solid fourth quarter and full year results," said MetLife
President and Chief Executive Officer Michel Khalaf. "We exceeded
our five-year Next Horizon commitments and begin our New Frontier
strategy from a position of strength with a greater emphasis on
responsible growth."
Fourth Quarter and Full Year 2024 Summary
($ in millions, except per share data)
Three Months Ended
December 31,
Year Ended December
31,
2024
2023
Change
2024
2023
Change
Premiums, fees and other revenues
$
14,475
$
13,687
6
%
$
52,520
$
51,961
1
%
Net investment income
5,405
5,366
1
%
21,273
19,908
7
%
Net investment gains (losses)
(311
)
(174
)
(1,184
)
(2,824
)
Net derivative gains (losses)
(903
)
149
(1,623
)
(2,140
)
Total revenues
$
18,666
$
19,028
$
70,986
$
66,905
Adjusted premiums, fees and other
revenues
$
14,437
$
13,671
6
%
$
52,379
$
51,966
1
%
Adjusted premiums, fees and other
revenues, excluding pension risk transfers (PRT)
$
11,844
$
11,811
$
47,530
$
46,642
2
%
Market risk benefit remeasurement gains
(losses)
$
764
$
(431
)
$
1,109
$
994
Net income (loss)
$
1,239
$
574
116
%
$
4,226
$
1,380
206
%
Net income (loss) per share
$
1.78
$
0.77
131
%
$
5.94
$
1.81
228
%
Adjusted earnings
$
1,459
$
1,361
7
%
$
5,796
$
5,525
5
%
Adjusted earnings per share
$
2.09
$
1.83
14
%
$
8.15
$
7.25
12
%
Adjusted earnings, excluding total notable
items
$
1,449
$
1,437
1
%
$
5,770
$
5,587
3
%
Adjusted earnings, excluding total notable
items per share
$
2.08
$
1.93
8
%
$
8.11
$
7.33
11
%
Book value per share
$
34.28
$
35.85
(4
)%
$
34.28
$
35.85
(4
)%
Adjusted book value* per share
$
54.81
$
53.75
2
%
$
54.81
$
53.75
2
%
Expense ratio
17.8
%
18.6
%
19.0
%
18.7
%
Direct expense ratio, excluding total
notable items related to direct expenses and PRT
13.1
%
12.4
%
12.1
%
12.2
%
Adjusted expense ratio, excluding total
notable items related to adjusted other expenses and PRT
21.9
%
20.6
%
20.9
%
20.5
%
ROE
19.6
%
9.6
%
16.9
%
5.4
%
Adjusted ROE*
15.4
%
13.8
%
15.2
%
13.6
%
Adjusted ROE,* excluding total notable
items
15.3
%
14.6
%
15.2
%
13.8
%
* Beginning with fourth quarter and full year 2024 results and
going forward, “adjusted book value” refers to book value,
excluding accumulated other comprehensive income (AOCI) other than
foreign currency translation adjustments (FCTA) and certain ceded
reinsurance-related embedded derivatives, and “adjusted ROE” refers
to ROE, excluding AOCI other than FCTA and certain ceded
reinsurance-related embedded derivatives. These changes did not
impact prior period amounts.
Information regarding the non-GAAP and other financial measures
included in this news release and reconciliation of the non-GAAP
financial measures to GAAP measures are in “Non-GAAP and Other
Financial Disclosures” below and in the tables that accompany this
news release.
Supplemental slides for the fourth quarter of 2024, titled “4Q24
Supplemental Slides and Outlook” are available on the MetLife
Investor Relations website at https://investor.metlife.com and in
the Form 8-K furnished by MetLife to the U.S. Securities and
Exchange Commission in connection with this earnings release.
Supplemental information about MetLife's diversified global
investment portfolio is contained in the "4Q24 - General Account
Assets Under Management Fact Sheet," available on the
above-mentioned website. Additionally, further information is
available under the heading "Consolidated Company Outlook" in Item
8.01 of the Form 8-K.
Total Company Discussion
MetLife reported fourth quarter 2024 premiums, fees and other
revenues of $14.5 billion, up 6 percent compared to the fourth
quarter of 2023. Adjusted premiums, fees and other revenues were
$14.4 billion, up 6 percent on a reported basis and up 7 percent on
a constant currency basis from the prior-year period.
Net investment income was $5.4 billion, up 1 percent from the
fourth quarter of 2023, primarily due to higher variable investment
income from higher private equity returns, asset growth and higher
rates, offset by decreases in the estimated fair value of certain
securities that do not qualify as separate accounts under GAAP.
Adjusted net investment income was $5.3 billion, up 5 percent,
primarily due to higher variable investment income and asset
growth.
Net investment losses were $311 million, or $246 million after
tax during the quarter, reflecting normal trading activity and a
stable credit environment. Net derivative losses amounted to $903
million, or $713 million after tax during the quarter, driven by an
increase in long-term interest rates and the strengthening of the
U.S. dollar versus the yen.
Net income was $1.2 billion, compared to net income of $574
million in the fourth quarter of 2023. The increase was primarily
driven by market risk benefit remeasurement gains and the positive
impact of higher adjusted earnings. This was partially offset by
higher net derivative losses. On a per-share basis, net income was
$1.78, compared to net income of $0.77 in the prior-year
period.
MetLife reported adjusted earnings of $1.5 billion, up 7 percent
on a reported basis, and up 10 percent on a constant currency
basis, from the fourth quarter of 2023. On a per-share basis,
adjusted earnings were $2.09, up 14 percent from the prior-year
period.
Adjusted Earnings by Segment Summary
Three Months Ended
December 31, 2024
Year Ended December 31,
2024
Segment
Change from prior-year
period (on a reported basis)
Change from prior-year
period (on a constant currency basis)
Change from prior
year
Change from prior
year (on a constant currency basis)
Group Benefits
(11)%
(3)%
Retirement and Income Solutions (RIS)
(8)%
(2)%
Asia
50%
52%
26%
30%
Latin America
(3)%
10%
5%
11%
Europe, the Middle East and Africa
(EMEA)
26%
31%
7%
12%
MetLife Holdings
(2)%
(12)%
Business Discussions
All comparisons of the results for the fourth quarter of 2024 in
the business discussions that follow are with the fourth quarter of
2023, unless otherwise noted.
GROUP BENEFITS
($ in millions)
Three Months Ended
December 31, 2024
Three Months Ended
December 31, 2023
Change
Adjusted earnings
$416
$466
(11)%
Notable item(s)
$0
$0
Adjusted earnings ex. notables
$416
$466
(11)%
Adjusted premiums, fees and other
revenues
$6,184
$6,001
3%
- Adjusted earnings were $416 million, down 11 percent,
primarily driven by lower non-medical health underwriting
margins.
- Adjusted premiums, fees and other revenues were $6.2
billion, up 3 percent, driven by growth in core and voluntary
products.
- Sales were up 8 percent for the year, primarily driven
by strong growth in national accounts.
RIS
($ in millions)
Three Months Ended
December 31, 2024
Three Months Ended
December 31, 2023
Change
Adjusted earnings
$386
$421
(8)%
Notable item(s)
$0
$0
Adjusted earnings ex. notables
$386
$421
(8)%
Adjusted premiums, fees and other
revenues
$3,620
$2,883
26%
Adjusted premiums, fees and other
revenues, excluding PRT
$1,027
$1,023
—%
- Adjusted earnings were $386 million, down 8 percent,
driven by lower recurring interest margins and less favorable
underwriting, partially offset by higher variable investment
income.
- Adjusted premiums, fees and other revenues were $3.6
billion, up 26 percent, driven by PRT, which includes UK funded
reinsurance.
- Excluding PRT, adjusted premiums, fees and other
revenues were $1.0 billion, essentially flat.
- Sales were up 45 percent for the year, driven by most
products, including U.S. pension risk transfer deals.
ASIA
($ in millions)
Three Months Ended
December 31, 2024
Three Months Ended
December 31, 2023
Change
Constant currency
change
Adjusted earnings
$443
$296
50%
52%
Notable item(s)
$0
$0
Adjusted earnings ex. notables
$443
$296
50%
52%
Adjusted premiums, fees and other
revenues
$1,635
$1,705
(4)%
(1)%
Asia general account assets under
management (at amortized cost)
$129,959
$130,093
—%
5%
- Adjusted earnings were $443 million, up 50 percent on a
reported basis, and up 52 percent on a constant currency basis,
driven by higher variable investment income and favorable
underwriting.
- Adjusted premiums, fees and other revenues were $1.6
billion, down 4 percent on a reported basis, and down 1 percent on
a constant currency basis.
- Asia general account assets under management (at amortized
cost) were $130.0 billion, essentially flat on a reported basis
and up 5 percent on a constant currency basis.
- Sales were $513 million, down 15 percent on a constant
currency basis, driven by lower sales in Japan, partially offset by
growth in Korea and India.
LATIN AMERICA
($ in millions)
Three Months Ended
December 31, 2024
Three Months Ended
December 31, 2023
Change
Constant currency
change
Adjusted earnings
$201
$207
(3)%
10%
Notable item(s)
$0
$0
Adjusted earnings ex. notables
$201
$207
(3)%
10%
Adjusted premiums, fees and other
revenues
$1,438
$1,486
(3)%
9%
- Adjusted earnings were $201 million, down 3 percent on a
reported basis, and up 10 percent on a constant currency basis,
driven by higher volume growth, partially offset by lower Chilean
encaje returns.
- Adjusted premiums, fees and other revenues were $1.4
billion, down 3 percent on a reported basis, and up 9 percent on a
constant currency basis, with strong growth and solid persistency
across the region.
- Sales were $335 million, up 9 percent on a constant
currency basis, led by growth in key markets.
EMEA
($ in millions)
Three Months Ended
December 31, 2024
Three Months Ended
December 31, 2023
Change
Constant currency
change
Adjusted earnings
$59
$47
26%
31%
Notable item(s)
$0
$0
Adjusted earnings ex. notables
$59
$47
26%
31%
Adjusted premiums, fees and other
revenues
$652
$595
10%
13%
- Adjusted earnings were $59 million, up 26 percent on a
reported basis and 31 percent on a constant currency basis, due to
volume growth and lower tax charges.
- Adjusted premiums, fees and other revenues were $652
million, up 10 percent on a reported basis and up 13 percent on a
constant currency basis due to strong sales across the region.
- Sales were $251 million, up 28 percent on a constant
currency basis.
METLIFE HOLDINGS
($ in millions)
Three Months Ended
December 31, 2024
Three Months Ended
December 31, 2023
Change
Adjusted earnings
$153
$156
(2)%
Notable item(s)
$0
$0
Adjusted earnings ex. notables
$153
$156
(2)%
Adjusted premiums, fees and other
revenues
$815
$901
(10)%
- Adjusted earnings were $153 million, down 2
percent, primarily as a result of the reinsurance transaction
completed in 2023, partially offset by favorable life underwriting
margins.
- Adjusted premiums, fees and other revenues were
$815 million, down 10 percent.
CORPORATE & OTHER
($ in millions)
Three Months Ended
December 31, 2024
Three Months Ended
December 31, 2023
Change
Adjusted earnings
$(199)
$(232)
Notable item(s)
$10
$(76)
Adjusted earnings ex. notables
$(209)
$(156)
- Adjusted loss of $199 million, compared to an adjusted
loss of $232 million in the prior-year period.
INVESTMENTS
($ in millions)
Three Months Ended
December 31, 2024
Three Months Ended
December 31, 2023
Change
Adjusted net investment income
$5,301
$5,047
5%
- Adjusted net investment income was $5.3 billion, up 5
percent, driven by variable investment income. Recurring investment
income was $5.0 billion, essentially flat compared to the
prior-year period. Variable investment income was $293 million,
compared to $63 million in the prior-year period, primarily driven
by higher private equity returns.
FOURTH QUARTER 2024 NOTABLE ITEMS
($ in millions)
Adjusted Earnings
Three Months Ended December
31, 2024
Notable Items
Group Benefits
RIS
Asia
Latin America
EMEA
MetLife
Holdings
Corporate &
Other
Total
Litigation reserves and settlement
costs
$0
$0
$0
$0
$0
$0
$(47)
$(47)
Tax adjustments
$0
$0
$0
$0
$0
$0
$57
$57
Total notable items
$0
$0
$0
$0
$0
$0
$10
$10
About MetLife
MetLife, Inc. (NYSE: MET), through its subsidiaries and
affiliates (“MetLife”), is one of the world’s leading financial
services companies, providing insurance, annuities, employee
benefits and asset management to help individual and institutional
customers build a more confident future. Founded in 1868, MetLife
has operations in more than 40 markets globally and holds leading
positions in the United States, Asia, Latin America, Europe and the
Middle East. For more information, visit www.metlife.com.
Conference Call
MetLife will hold its combined fourth quarter and full year 2024
earnings and outlook conference call and audio webcast on Thursday,
February 6, 2025, from 9-10 a.m. (ET). The conference call will be
available live via the internet. To listen to the conference call,
click the following link to register
(https://registrations.events/direct/Q4I757070).
The conference call will be available for replay via telephone
and the internet beginning at 11:00 a.m. (ET) on Thursday, February
6, 2025, until Thursday, February 13, 2025, at 11:59 p.m. (ET). To
listen to a replay of the conference call via telephone, dial
800-770-2030 (U.S.) or 647-362-9199 (outside the U.S.). The
Conference ID for the replay is 75707. To access the replay of the
conference call via the internet, visit the MetLife Investor
Relations webpage (https://investor.metlife.com).
Non-GAAP and Other Financial
Disclosures
Any references in this news release
(except in this section and the tables that accompany this release)
to:
should be read as,
respectively:
(i)
net income (loss);
(i)
net income (loss) available to MetLife,
Inc.’s common shareholders;
(ii)
net income (loss) per share;
(ii)
net income (loss) available to MetLife,
Inc.’s common shareholders per diluted common share;
(iii)
adjusted earnings;
(iii)
adjusted earnings available to common
shareholders;
(iv)
adjusted earnings per share;
(iv)
adjusted earnings available to common
shareholders per diluted common share;
(v)
book value per share;
(v)
book value per common share;
(vi)
adjusted book value per share;
(vi)
adjusted book value per common share;
(vii)
return on equity; and
(vii)
return on MetLife, Inc.’s common
stockholders’ equity; and
(viii)
adjusted return on equity.
(viii)
adjusted return on MetLife, Inc.’s
common
stockholders’ equity.
In this news release, MetLife presents certain measures of its
performance on a consolidated and segment basis that are not
calculated in accordance with accounting principles generally
accepted in the United States of America (GAAP). MetLife believes
that these non-GAAP financial measures enhance our investors'
understanding of MetLife's performance by highlighting the results
of operations and the underlying profitability drivers of the
business. Segment-specific financial measures are calculated using
only the portion of consolidated results attributable to that
specific segment.
The following non-GAAP financial measures should not be viewed
as substitutes for the most directly comparable financial measures
calculated in accordance with GAAP:
Non-GAAP financial measures:
Comparable GAAP financial
measures:
(i)
total adjusted revenues;
(i)
total revenues;
(ii)
total adjusted expenses;
(ii)
total expenses;
(iii)
adjusted premiums, fees and other
revenues;
(iii)
premiums, fees and other revenues;
(iv)
adjusted premiums, fees and other
revenues, excluding PRT;
(iv)
premiums, fees and other revenues;
(v)
adjusted net investment income;
(v)
net investment income;
(vi)
adjusted earnings available to common
shareholders;
(vi)
net income (loss) available to MetLife,
Inc.’s common shareholders;
(vii)
adjusted earnings available to common
shareholders, excluding total notable items;
(vii)
net income (loss) available to MetLife,
Inc.’s common shareholders;
(viii)
adjusted earnings available to common
shareholders per diluted common share;
(viii)
net income (loss) available to MetLife,
Inc.’s common shareholders per diluted common share;
(ix)
adjusted earnings available to common
shareholders, excluding total notable items, per diluted common
share;
(ix)
net income (loss) available to MetLife,
Inc.’s common shareholders per diluted common share;
(x)
adjusted return on equity;
(x)
return on equity;
(xi)
adjusted return on equity, excluding total
notable items;
(xi)
return on equity;
(xii)
investment portfolio gains (losses);
(xii)
net investment gains (losses);
(xiii)
derivative gains (losses);
(xiii)
net derivative gains (losses);
(xiv)
adjusted capitalization of deferred policy
acquisition costs (DAC);
(xiv)
capitalization of DAC;
(xv)
total MetLife, Inc.’s adjusted common
stockholders’ equity;
(xv)
total MetLife, Inc.’s stockholders’
equity;
(xvi)
total MetLife, Inc.’s adjusted common
stockholders’ equity, excluding total notable items;
(xvi)
total MetLife, Inc.’s stockholders’
equity;
(xvii)
adjusted book value per common share;
(xvii)
book value per common share;
(xviii)
adjusted other expenses;
(xviii)
other expenses;
(xix)
adjusted other expenses, net of adjusted
capitalization of DAC;
(xix)
other expenses, net of capitalization of
DAC;
(xx)
adjusted other expenses, net of adjusted
capitalization of DAC, excluding total notable items related to
adjusted other expenses;
(xx)
other expenses, net of capitalization of
DAC;
(xxi)
adjusted expense ratio;
(xxi)
expense ratio;
(xxii)
adjusted expense ratio, excluding total
notable items related to adjusted other expenses and PRT;
(xxii)
expense ratio;
(xxiii)
direct expenses;
(xxiii)
other expenses;
(xxiv)
direct expenses, excluding total notable
items related to direct expenses;
(xxiv)
other expenses;
(xxv)
direct expense ratio;
(xxv)
expense ratio;
(xxvi)
direct expense ratio, excluding total
notable items related to direct expenses and PRT;
(xxvi)
expense ratio;
(xxvii)
future policy benefits at original
discount rate; and
(xxvii)
future policy benefits at balance sheet
discount rate; and
(xxviii)
free cash flow of all holding
companies.
(xxviii)
MetLife, Inc. (parent company only) net
cash provided by (used in) operating activities.
Any of these financial measures shown on a constant currency
basis reflect the impact of changes in foreign currency exchange
rates and are calculated using the average foreign currency
exchange rates for the current period and applied to the comparable
prior period (“constant currency basis”).
Reconciliations of these non-GAAP financial measures to the most
directly comparable GAAP financial measures are included in this
earnings news release and in this period’s quarterly financial
supplement, which is available at https://investor.metlife.com.
MetLife’s definitions of non-GAAP and other financial measures
discussed in this news release may differ from those used by other
companies:
Adjusted earnings and related measures
- adjusted earnings;
- adjusted earnings available to common shareholders;
- adjusted earnings available to common shareholders on a
constant currency basis;
- adjusted earnings available to common shareholders, excluding
total notable items;
- adjusted earnings available to common shareholders, excluding
total notable items, on a constant currency basis;
- adjusted earnings available to common shareholders per diluted
common share;
- adjusted earnings available to common shareholders on a
constant currency basis per diluted common share;
- adjusted earnings available to common shareholders, excluding
total notable items per diluted common share; and
- adjusted earnings available to common shareholders, excluding
total notable items, on a constant currency basis per diluted
common share.
Adjusted earnings is used by the Company’s chief operating
decision maker, its chief executive officer, to evaluate
performance and allocate resources. Consistent with GAAP guidance
for segment reporting, adjusted earnings is MetLife’s GAAP measure
of segment performance. Adjusted earnings and related measures
based on adjusted earnings are also the measures by which senior
management’s and many other employees’ performance is evaluated for
the purposes of determining their compensation under applicable
compensation plans. Adjusted earnings and related measures based on
adjusted earnings allow analysis of MetLife's performance relative
to its business plan and facilitate comparisons to industry
results.
Adjusted earnings is defined as adjusted revenues less adjusted
expenses, net of income tax. Adjusted earnings available to common
shareholders is defined as adjusted earnings less preferred stock
dividends.
Adjusted earnings, along with the related adjusted revenues,
adjusted expenses and adjusted premiums, fees and other revenues,
focus on our primary businesses principally by excluding the impact
of (i) market volatility which could distort trends, (ii)
asymmetrical and non-economic accounting, (iii) revenues and costs
related to divested businesses, and (iv) other adjustments. Also,
adjusted earnings and related measures exclude results of
discontinued operations under GAAP.
Market volatility can have a significant impact on MetLife’s
financial results. Adjusted earnings excludes net investment gains
(losses), net derivative gains (losses), market risk benefits
remeasurement gains (losses) and goodwill impairments. Further, net
investment income excludes adjusted earnings adjustments relating
to joint ventures accounted for under the equity method ("Joint
venture adjustments"), and policyholder benefits and claims exclude
(i) changes in the discount rate on certain annuitization
guarantees accounted for as additional liabilities and (ii) market
value adjustments.
Asymmetrical and non-economic accounting adjustments are made to
the line items indicated in calculating adjusted earnings:
- Net investment income includes earned income on derivatives and
amortization of premium on derivatives that are hedges of
investments or that are used to replicate certain investments, but
do not qualify for hedge accounting treatment ("Investment hedge
adjustments").
- Other revenues include settlements of foreign currency earnings
hedges and exclude asymmetrical accounting associated with in-force
reinsurance.
- Policyholder benefits and claims excludes (i) amortization of
basis adjustments associated with de-designated fair value hedges
of future policy benefits, (ii) inflation-indexed benefit
adjustments associated with contracts backed by inflation-indexed
investments, (iii) asymmetrical accounting associated with in-force
reinsurance, and (iv) non-economic losses incurred at contract
inception for certain single premium annuity business. These losses
are amortized into adjusted earnings within policyholder benefits
and claims over the estimated lives of the contracts.
- Policyholder liability remeasurement gains (losses) excludes
asymmetrical accounting associated with in-force reinsurance.
- Interest credited to policyholder account balances excludes
amounts associated with periodic crediting rate adjustments based
on the total return of a contractually referenced pool of assets
and other pass-through adjustments and asymmetrical accounting
associated with in-force reinsurance.
Divested businesses are those that have been or will be sold or
exited by MetLife but do not meet the discontinued operations
criteria under GAAP. Divested businesses also include the net
impact of transactions with exited businesses that have been
eliminated in consolidation under GAAP and costs relating to
businesses that have been or will be sold or exited by MetLife that
do not meet the criteria to be included in results of discontinued
operations under GAAP.
Other adjustments are made in calculating adjusted earnings:
- Net investment income and interest credited to policyholder
account balances excludes certain amounts related to
contractholder-directed equity securities ("Unit-linked contract
income") and ("Unit-linked contract costs"). Net investment income
excludes returns on invested assets (including cash and cash
equivalents) subject to ceded reinsurance arrangements with third
parties ("Reinsurance adjustments").
- Other revenues include fee revenue on synthetic guaranteed
interest contracts ("GICs") accounted for as freestanding
derivatives.
- Other revenues exclude and other expenses include fees received
in connection with services provided under transition service
agreements.
- Other expenses exclude (i) Reinsurance adjustments, (ii)
implementation of new insurance regulatory requirements and other
costs, and (iii) acquisition, integration and other related costs.
Other expenses include (i) deductions for net income attributable
to noncontrolling interests, and (ii) benefits accrued on synthetic
GICs accounted for as freestanding derivatives.
Adjusted earnings also excludes the recognition of certain
contingent assets and liabilities that could not be recognized at
acquisition or adjusted for during the measurement period under
GAAP business combination accounting guidance.
The tax impact of the adjustments mentioned above are calculated
net of the U.S. or foreign statutory tax rate, which could differ
from MetLife's effective tax rate. Additionally, the provision for
income tax (expense) benefit also includes the impact related to
the timing of certain tax credits, as well as certain tax
reforms.
In addition, adjusted earnings available to common shareholders
excludes the impact of preferred stock redemption premium, which is
reported as a reduction to net income (loss) available to MetLife,
Inc.’s common shareholders.
Investment portfolio gains (losses) and derivative gains
(losses)
These are measures of investment and hedging activity.
Investment portfolio gains (losses) principally excludes amounts
that are reported within net investment gains (losses) but do not
relate to the performance of the investment portfolio, such as
gains (losses) on sales and divestitures of businesses, as well as
investment portfolio gains (losses) of divested businesses.
Derivative gains (losses) principally excludes earned income on
derivatives and amortization of premium on derivatives, where such
derivatives are either hedges of investments or are used to
replicate certain investments, and where such derivatives do not
qualify for hedge accounting. This earned income and amortization
of premium is reported within adjusted earnings and not within
derivative gains (losses).
Return on equity and related measures
- Total MetLife, Inc.’s adjusted common
stockholders’ equity: total MetLife, Inc.’s common
stockholders’ equity, excluding unrealized investment gains
(losses), net of related offsets, deferred gains (losses) on
derivatives, future policy benefits discount rate remeasurement
gains (losses), market risk benefits instrument-specific credit
risk remeasurement gains (losses) and defined benefit plans
adjustment components of AOCI (AOCI other than FCTA) and the
estimated fair value of certain ceded reinsurance-related embedded
derivatives, all net of income tax.
- Total MetLife, Inc.’s adjusted common
stockholders’ equity, excluding total notable items: total
MetLife, Inc.’s common stockholders’ equity, excluding unrealized
investment gains (losses), net of related offsets, deferred gains
(losses) on derivatives, future policy benefits discount rate
remeasurement gains (losses), market risk benefits
instrument-specific credit risk remeasurement gains (losses) and
defined benefit plans adjustment components of AOCI (AOCI other
than FCTA), the estimated fair value of certain ceded
reinsurance-related embedded derivatives and total notable items,
all net of income tax.
- Return on MetLife, Inc.’s common
stockholders’ equity: net income (loss) available to
MetLife, Inc.’s common shareholders divided by MetLife, Inc.’s
average common stockholders’ equity.
- Adjusted return on MetLife, Inc.'s common
stockholders' equity: adjusted earnings available to common
shareholders divided by MetLife, Inc.'s average adjusted common
stockholders' equity.
- Adjusted return on MetLife, Inc.'s common
stockholders' equity, excluding total notable items:
adjusted earnings available to common shareholders, excluding total
notable items, divided by MetLife, Inc.'s average adjusted common
stockholders' equity, excluding total notable items. The above
measures represent a level of equity that excludes most components
of AOCI, such as unrealized investment gains (losses) and future
policy benefits discount rate remeasurement gains (losses), as well
as the impact of certain ceded reinsurance-related embedded
derivatives, as these amounts are primarily driven by market
volatility.
Expense ratio, direct expense ratio, adjusted expense ratio
and related measures
- Expense ratio: other expenses, net
of capitalization of DAC, divided by premiums, fees and other
revenues.
- Direct expense ratio: adjusted
direct expenses, divided by adjusted premiums, fees and other
revenues. Direct expenses are comprised of employee-related costs,
third-party staffing costs, and general and administrative
expenses.
- Direct expense ratio, excluding total
notable items related to direct expenses and PRT: adjusted
direct expenses, excluding total notable items related to direct
expenses, divided by adjusted premiums, fees and other revenues,
excluding PRT.
- Adjusted expense ratio: adjusted
other expenses, net of adjusted capitalization of DAC, divided by
adjusted premiums, fees and other revenues.
- Adjusted expense ratio, excluding total
notable items related to adjusted other expenses and PRT:
adjusted other expenses, net of adjusted capitalization of DAC,
excluding total notable items related to adjusted other expenses,
divided by adjusted premiums, fees and other revenues, excluding
PRT.
Asia general account (GA) assets under management (GA AUM)
and related measures
Asia GA AUM is used by MetLife to describe assets in its Asia GA
investment portfolio. Asia GA AUM is stated at estimated fair value
and is comprised of Asia GA total investments, the portion of the
Asia GA investment portfolio classified within assets
held-for-sale, cash and cash equivalents, and accrued investment
income on such assets, excluding policy loans,
contractholder-directed equity securities, fair value option
securities, mortgage loans originated for third parties, assets
subject to reinsurance arrangements with third-party reinsurers,
and certain other invested assets. Mortgage loans, net of mortgage
loans originated for third parties ("net mortgage loans")
(including commercial ("net commercial mortgage loans"),
agricultural ("net agricultural mortgage loans") and residential
mortgage loans) and real estate equity (including real estate and
real estate joint ventures) included in Asia GA AUM (at net asset
value, net of deduction for encumbering debt) have been adjusted
from carrying value to estimated fair value. At the segment level,
intersegment balances (intercompany activity, primarily related to
investments in subsidiaries, that eliminate at the MetLife
consolidated level) are excluded from Asia GA AUM.
Asia GA AUM (at amortized cost) excludes the following
adjustments: (i) unrealized gain (loss) on investments carried at
estimated fair value and (ii) adjustments from carrying value to
estimated fair value on net mortgage loans (including net
commercial mortgage loans, net agricultural mortgage loans and
residential mortgage loans) and real estate and real estate joint
ventures. Asia GA AUM (at amortized cost) is presented net of
related allowance for credit loss.
Statistical sales information:
- Group Benefits: calculated using 10% of single premium deposits
and 100% of annualized full-year premiums and fees from recurring
premium policy sales of all products.
- RIS: calculated using 10% of single premium contracts, on and
off-balance sheet deposits, and the contract value for new UK
longevity reinsurance contracts, and 100% of annualized full-year
premiums and fees only from recurring premium policy sales of
specialized benefit resources and corporate-owned life
insurance.
- Asia, Latin America and EMEA: calculated using 10% of single
premium deposits (mainly from retirement products such as variable
annuity, fixed annuity and pensions), 20% of single premium
deposits from credit insurance and 100% of annualized full-year
premiums and fees from recurring-premium policy sales of all
products (mainly from risk and protection products such as
individual life, accident & health and group).
Sales statistics do not correspond to revenues under GAAP, but
are used as relevant measures of business activity.
The following additional information is relevant to an
understanding of MetLife’s performance results and outlook:
- Volume growth, as discussed in the context of business growth,
is the period over period percentage change in adjusted earnings
available to common shareholders attributable to adjusted premiums,
fees and other revenues and assets under management levels,
applying a model in which certain margins and factors are held
constant. The most significant of such items are underwriting
margins, investment margins, changes in equity market performance,
expense margins and the impact of changes in foreign currency
exchange rates.
- PRT includes UK funded reinsurance.
- Holding company cash and liquid assets are held by MetLife,
Inc. collectively with other MetLife holding companies and include
cash and cash equivalents, short term investments and publicly
traded securities excluding assets that are pledged or otherwise
committed. Assets pledged or otherwise committed include amounts
received in connection with securities lending, repurchase
agreements, derivatives, regulatory deposits, the collateral
financing arrangement, funding agreements and secured borrowings,
as well as amounts held in the closed block.
- MetLife uses a measure of free cash flow to facilitate an
understanding of its ability to generate cash for reinvestment into
its businesses or use in non-mandatory capital actions. MetLife
defines free cash flow as the sum of cash available at MetLife’s
holding companies from dividends from operating subsidiaries,
expenses and other net flows of the holding companies (including
capital contributions to subsidiaries), and net contributions from
debt to be at or below target leverage ratios. This measure of free
cash flow is prior to capital actions, such as common stock
dividends and repurchases, debt reduction and mergers and
acquisitions. Free cash flow should not be viewed as a substitute
for net cash provided by (used in) operating activities calculated
in accordance with GAAP. The free cash flow ratio is typically
expressed as a percentage of annual adjusted earnings available to
common shareholders.
- Notable items reflect the unexpected impact of events that
affect MetLife’s results, but that were unknown and that MetLife
could not anticipate when it devised its business plan. Notable
items also include certain items regardless of the extent
anticipated in the business plan, to help investors have a better
understanding of MetLife's results and to evaluate and forecast
those results. Notable items represent a positive (negative) impact
to adjusted earnings available to common shareholders.
- We refer to observable forward yield curves as of a particular
date in connection with making our estimates for future results.
The observable forward yield curves at a given time are based on
implied future interest rates along a range of interest rate
durations. This includes the 10-year U.S. Treasury rate which we
use as a benchmark rate to describe longer-term interest rates used
in our estimates for future results.
Forward-Looking Statements
This news release may contain or incorporate by reference
information that includes or is based upon forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements give expectations or
forecasts of future events and do not relate strictly to historical
or current facts. They use words and terms such as “anticipate,”
"are confident," “assume,” “believe,” “continue,” “could,”
“estimate,” “expect,” “if,” “intend,” “likely,” “may,” “plan,”
“potential,” “project,” “should,” "target," “will,” “would,” and
other words and terms of similar meaning or that are otherwise tied
to future periods or future performance, in each case in all
derivative forms. They include statements relating to strategy,
goals and expectations concerning our market position, future
operations, margins, profitability, capital expenditures, liquidity
and capital resources and other financial and operating
information. By their nature, forward-looking statements: speak
only as of the date they are made; are not statements of historical
fact or guarantees of future performance; and are subject to risks,
uncertainties, assumptions or changes in circumstances that are
difficult to predict or quantify. Our expectations, beliefs and
projections are expressed in good faith and we believe there is a
reasonable basis for them. However, there can be no assurance that
management’s expectations, beliefs and projections will result or
be achieved and actual results may vary materially from what is
expressed in or indicated by the forward-looking statements.
Many factors determine the results of MetLife, Inc., its
subsidiaries and affiliates, and they involve unpredictable risks
and uncertainties. Our forward-looking statements depend on our
assumptions, our expectations, and our understanding of the
economic environment, but they may be inaccurate and may change.
MetLife, Inc. does not guarantee any future performance. Our
results could differ materially from those MetLife, Inc. expresses
or implies in forward-looking statements. The risks, uncertainties
and other factors identified in MetLife, Inc.’s filings with the
U.S. Securities and Exchange Commission, and others, may cause such
differences. These factors include:
(1)
economic condition difficulties, including
risks relating to interest rates, credit spreads, declining equity
or debt markets, real estate, obligors and counterparties,
government default, currency exchange rates, derivatives, climate
change, public health and terrorism and security;
(2)
global capital and credit market
adversity;
(3)
credit facility inaccessibility;
(4)
financial strength or credit ratings
downgrades;
(5)
unavailability, unaffordability, or
inadequate reinsurance, including reinsurance risks that arise from
reinsurers' credit risk, and the potential shortfall or failure of
risk mitigants to protect against such risks;
(6)
statutory life insurance reserve financing
costs or limited market capacity;
(7)
legal, regulatory, and supervisory and
enforcement policy changes;
(8)
changes in tax rates, tax laws or
interpretations;
(9)
litigation and regulatory
investigations;
(10)
unsuccessful efforts to meet all
environmental, social, and governance standards or to enhance our
sustainability;
(11)
MetLife, Inc.’s inability to pay dividends
and repurchase common stock;
(12)
MetLife, Inc.’s subsidiaries’ inability to
pay dividends to MetLife, Inc.;
(13)
investment defaults, downgrades, or
volatility;
(14)
investment sales or lending
difficulties;
(15)
collateral or derivative-related
payments;
(16)
investment valuations, allowances, or
impairments changes;
(17)
claims or other results that differ from
our estimates, assumptions, or models;
(18)
global political, legal, or operational
risks;
(19)
business competition;
(20)
technological changes;
(21)
catastrophes;
(22)
climate changes or responses to it;
(23)
deficiencies in our closed block;
(24)
goodwill or other asset impairment, or
deferred income tax asset allowance;
(25)
impairment of VOBA, value of distribution
agreements acquired or value of customer relationships
acquired;
(26)
product guarantee volatility, costs, and
counterparty risks;
(27)
risk management failures;
(28)
insufficient protection from operational
risks;
(29)
failure to protect confidentiality,
integrity or availability of systems or data or other cybersecurity
or disaster recovery failures;
(30)
accounting standards changes;
(31)
excessive risk-taking;
(32)
marketing and distribution
difficulties;
(33)
pension and other postretirement benefit
assumption changes;
(34)
inability to protect our intellectual
property or avoid infringement claims;
(35)
acquisition, integration, growth,
disposition, or reorganization difficulties;
(36)
Brighthouse Financial, Inc. separation
risks;
(37)
MetLife, Inc.’s Board of Directors
influence over the outcome of stockholder votes through the voting
provisions of the MetLife Policyholder Trust; and
(38)
legal- and corporate governance-related
effects on business combinations.
MetLife, Inc. does not undertake any obligation to publicly
correct or update any forward-looking statement if MetLife, Inc.
later becomes aware that such statement is not likely to be
achieved. Please consult any further disclosures MetLife, Inc.
makes on related subjects in subsequent reports to the U.S.
Securities and Exchange Commission.
MetLife, Inc.
GAAP Consolidated Statements
of Operations
(In millions)
For the Three Months
Ended
For the Year Ended
December 31,
December 31,
2024
2023
2024
2023
Revenues
Premiums
$
12,617
$
11,786
$
44,945
$
44,283
Universal life and investment-type product
policy fees
1,217
1,241
4,974
5,152
Net investment income
5,405
5,366
21,273
19,908
Other revenues
641
660
2,601
2,526
Net investment gains (losses)
(311
)
(174
)
(1,184
)
(2,824
)
Net derivative gains (losses)
(903
)
149
(1,623
)
(2,140
)
Total revenues
18,666
19,028
70,986
66,905
Expenses
Policyholder benefits and claims
12,572
11,779
44,728
44,590
Policyholder liability remeasurement
(gains) losses
(42
)
(3
)
(206
)
(45
)
Market risk benefit remeasurement (gains)
losses
(764
)
431
(1,109
)
(994
)
Interest credited to policyholder account
balances
2,012
2,405
8,339
7,860
Policyholder dividends
150
159
595
622
Amortization of DAC, VOBA and negative
VOBA
517
498
2,021
1,926
Interest expense on debt
259
269
1,037
1,045
Other expenses, net of capitalization of
DAC
2,581
2,549
9,959
9,739
Total expenses
17,285
18,087
65,364
64,743
Income (loss) before provision for income
tax
1,381
941
5,622
2,162
Provision for income tax expense
(benefit)
106
327
1,178
560
Net income (loss)
1,275
614
4,444
1,602
Less: Net income (loss) attributable to
noncontrolling interests
4
7
18
24
Net income (loss) attributable to MetLife,
Inc.
1,271
607
4,426
1,578
Less: Preferred stock dividends
32
33
200
198
Net income (loss) available to MetLife,
Inc.'s common shareholders
$
1,239
$
574
$
4,226
$
1,380
See footnotes on last page.
MetLife, Inc.
(In millions, except per share
data)
For the Three Months
Ended
For the Year Ended
December 31,
December 31,
2024
2023
2024
2023
Reconciliation to Adjusted Earnings
Available to Common Shareholders
Earnings Per Weighted
Average Common Share Diluted (1)
Earnings Per Weighted
Average Common Share Diluted (1)
Earnings Per Weighted
Average
Common Share Diluted
(1)
Earnings Per Weighted
Average Common Share Diluted (1)
Net income (loss) available to MetLife,
Inc.'s common shareholders
$
1,239
$
1.78
$
574
$
0.77
$
4,226
$
5.94
$
1,380
$
1.81
Adjustments from net income (loss)
available to common shareholders to adjusted earnings available to
common shareholders:
Less: Net investment gains (losses)
(311
)
(0.45
)
(174
)
(0.23
)
(1,184
)
(1.67
)
(2,824
)
(3.70
)
Net derivative gains (losses)
(903
)
(1.29
)
149
0.20
(1,623
)
(2.28
)
(2,140
)
(2.81
)
Market risk benefit remeasurement gains
(losses)
764
1.09
(431
)
(0.58
)
1,109
1.56
994
1.30
Premiums
15
0.02
—
—
31
0.04
—
—
Universal life and investment-type product
policy fees
—
—
—
—
—
—
—
—
Net investment income
104
0.15
319
0.43
601
0.85
159
0.21
Other revenues
23
0.03
16
0.02
110
0.15
(5
)
(0.01
)
Policyholder benefits and claims and
policyholder dividends
(12
)
(0.02
)
36
0.05
18
0.03
5
0.01
Policyholder liability remeasurement
(gains) losses
—
—
—
—
—
—
—
—
Interest credited to policyholder account
balances
(180
)
(0.23
)
(685
)
(0.93
)
(1,184
)
(1.67
)
(1,251
)
(1.65
)
Capitalization of DAC
—
—
—
—
—
—
—
—
Amortization of DAC, VOBA and negative
VOBA
—
—
—
—
—
—
—
—
Interest expense on debt
—
—
—
—
—
—
—
—
Other expenses
(68
)
(0.10
)
(16
)
(0.02
)
(117
)
(0.16
)
(93
)
(0.12
)
Goodwill impairment
—
—
—
—
—
—
—
—
Provision for income tax (expense)
benefit
352
0.50
6
0.01
687
0.97
1,034
1.36
Add: Net income (loss) attributable to
noncontrolling interests
4
0.01
7
0.01
18
0.03
24
0.03
Preferred stock redemption premium
—
—
—
—
—
—
—
—
Adjusted earnings available to common
shareholders
1,459
2.09
1,361
1.83
5,796
8.15
5,525
7.25
Less: Total notable items
10
0.01
(76
)
(0.10
)
26
0.04
(62
)
(0.08
)
Adjusted earnings available to common
shareholders, excluding total notable items
$
1,449
$
2.08
$
1,437
$
1.93
$
5,770
$
8.11
$
5,587
$
7.33
Adjusted earnings available to common
shareholders on a constant currency basis
$
1,459
$
2.09
$
1,329
$
1.79
$
5,796
$
8.15
$
5,430
$
7.12
Adjusted earnings available to common
shareholders, excluding total notable items, on a constant currency
basis
$
1,449
$
2.08
$
1,405
$
1.89
$
5,770
$
8.11
$
5,492
$
7.20
Weighted average common shares outstanding
- diluted
697.9
743.4
711.1
762.3
See footnotes on last page.
MetLife, Inc.
(In millions)
For the Three Months
Ended
For the Year Ended
December 31,
December 31,
2024
2023
2024
2023
Premiums, Fees and Other
Revenues
Premiums, fees and other revenues
$
14,475
$
13,687
$
52,520
$
51,961
Less: Adjustments to premiums, fees and
other revenues:
Asymmetrical and non-economic
accounting
34
29
158
29
Other adjustments
(11
)
(13
)
(48
)
(34
)
Divested businesses
15
—
31
—
Adjusted premiums, fees and other
revenues
$
14,437
$
13,671
$
52,379
$
51,966
Adjusted premiums, fees and other
revenues, on a constant currency basis
$
14,437
$
13,440
$
52,379
$
51,966
Less: PRT
2,593
1,860
4,849
5,324
Adjusted premiums, fees and other
revenues, excluding PRT, on a constant currency basis
$
11,844
$
11,580
$
47,530
$
46,642
Net Investment Income
Net investment income
$
5,405
$
5,366
$
21,273
$
19,908
Less: Adjustments to net investment
income
Investment hedge adjustments
(127
)
(253
)
(604
)
(1,012
)
Joint venture adjustments
16
(8
)
82
(12
)
Unit-linked contract income and
reinsurance adjustments
214
580
1,122
1,183
Divested businesses
1
—
1
—
Adjusted net investment income
$
5,301
$
5,047
$
20,672
$
19,749
Revenues and Expenses
Total revenues
$
18,666
$
19,028
$
70,986
$
66,905
Less: Adjustments to total revenues:
Net investment gains (losses)
(311
)
(174
)
(1,184
)
(2,824
)
Net derivative gains (losses)
(903
)
149
(1,623
)
(2,140
)
Investment hedge adjustments
(127
)
(253
)
(604
)
(1,012
)
Asymmetrical and non-economic
accounting
34
29
158
29
Joint venture adjustments
16
(8
)
82
(12
)
Unit-linked contract income and
reinsurance adjustments
214
580
1,122
1,183
Other adjustments
(11
)
(13
)
(48
)
(34
)
Divested businesses
16
—
32
—
Total adjusted revenues
$
19,738
$
18,718
$
73,051
$
71,715
Total expenses
$
17,285
$
18,087
$
65,364
$
64,743
Less: Adjustments to total expenses:
Market risk benefit remeasurement (gains)
losses
(764
)
431
(1,109
)
(994
)
Goodwill impairment
—
—
—
—
Asymmetrical and non-economic
accounting
46
129
322
247
Market volatility
(49
)
(62
)
(256
)
(184
)
Unit-linked contract costs and reinsurance
adjustments
215
582
1,111
1,183
Other adjustments
25
7
49
55
Divested businesses
23
9
57
38
Total adjusted expenses
$
17,789
$
16,991
$
65,190
$
64,398
See footnotes on last page.
MetLife, Inc.
(In millions, except per share
and ratio data)
For the Three Months
Ended
For the Year Ended
December 31,
December 31,
2024
2023
2024
2023
Expense Detail and Ratios
Reconciliation of Capitalization of DAC
to Adjusted Capitalization of DAC
Capitalization of DAC
$
(719
)
$
(728
)
$
(2,833
)
$
(2,917
)
Less: Divested businesses
—
—
—
—
Adjusted capitalization of DAC
$
(719
)
$
(728
)
$
(2,833
)
$
(2,917
)
Reconciliation of Other Expenses to
Adjusted Other Expenses
Other expenses
$
3,300
$
3,277
$
12,792
$
12,656
Less: Reinsurance adjustments
30
—
30
—
Less: Other adjustments
25
7
49
55
Less: Divested businesses
13
9
38
38
Adjusted other expenses
$
3,232
$
3,261
$
12,675
$
12,563
Other Detail and Ratios
Other expenses, net of capitalization of
DAC
$
2,581
$
2,549
$
9,959
$
9,739
Premiums, fees and other revenues
$
14,475
$
13,687
$
52,520
$
51,961
Expense ratio
17.8
%
18.6
%
19.0
%
18.7
%
Direct expenses
$
1,396
$
1,559
$
5,611
$
5,808
Less: Total notable items related to
direct expenses
(152
)
96
(152
)
96
Direct expenses, excluding total notable
items related to direct expenses
$
1,548
$
1,463
$
5,763
$
5,712
Adjusted other expenses
$
3,232
$
3,261
$
12,675
$
12,563
Adjusted capitalization of DAC
(719
)
(728
)
(2,833
)
(2,917
)
Adjusted other expenses, net of adjusted
capitalization of DAC
2,513
2,533
9,842
9,646
Less: Total notable items related to
adjusted other expenses
(85
)
96
(85
)
96
Adjusted other expenses, net of adjusted
capitalization of DAC, excluding total notable items related to
adjusted other expenses
$
2,598
$
2,437
$
9,927
$
9,550
Adjusted premiums, fees and other
revenues
$
14,437
$
13,671
$
52,379
$
51,966
Less: PRT
2,593
1,860
4,849
5,324
Adjusted premiums, fees and other
revenues, excluding PRT
$
11,844
$
11,811
$
47,530
$
46,642
Direct expense ratio
9.7
%
11.4
%
10.7
%
11.2
%
Direct expense ratio, excluding total
notable items related to direct expenses and PRT
13.1
%
12.4
%
12.1
%
12.2
%
Adjusted expense ratio
17.4
%
18.5
%
18.8
%
18.6
%
Adjusted expense ratio, excluding total
notable items related to adjusted other expenses and PRT
21.9
%
20.6
%
20.9
%
20.5
%
See footnotes on last page.
MetLife, Inc.
(In millions, except per share
data)
December 31,
Equity Details
2024
2023
Total MetLife, Inc.'s stockholders'
equity
$
27,445
$
30,015
Less: Preferred stock
3,818
3,818
MetLife, Inc.'s common stockholders'
equity
23,627
26,197
Less: Unrealized investment gains
(losses), net of related offsets and income tax
(19,402
)
(14,506
)
Deferred gains (losses) on derivatives,
net of income tax
370
183
Future policy benefits discount rate
remeasurement gain (losses), net of income tax
6,529
2,658
Market risk benefits instrument-specific
credit risk remeasurement gains (losses), net of income tax
(71
)
27
Defined benefit plans adjustment, net of
income tax
(1,442
)
(1,446
)
Estimated fair value of certain ceded
reinsurance-related embedded derivatives, net of income tax
(129
)
—
Total MetLife, Inc.'s adjusted common
stockholders' equity
37,772
39,281
Less: Accumulated year-to-date total
notable items, net of income tax
26
(62
)
Total MetLife, Inc.'s adjusted common
stockholders' equity, excluding total notable items
$
37,746
$
39,343
December 31,
Book Value (2)
2024
2023
Book value per common share
34.28
35.85
Less: Unrealized investment gains
(losses), net of related offsets and income tax
(28.15
)
(19.85
)
Deferred gains (losses) on derivatives,
net of income tax
0.54
0.25
Future policy benefits discount rate
remeasurement gain (losses), net of income tax
9.46
3.64
Market risk benefits instrument-specific
credit risk remeasurement gains (losses), net of income tax
(0.10
)
0.04
Defined benefit plans adjustment, net of
income tax
(2.09
)
(1.98
)
Estimated fair value of certain ceded
reinsurance-related embedded derivatives, net of income tax
(0.19
)
—
Adjusted book value per common share
$
54.81
$
53.75
Common shares outstanding, end of period
(3)
689.2
730.8
For the Three Months
Ended
For the Year Ended
December 31, (4)
December 31,
Return on Equity
2024
2023
2024
2023
Return on MetLife, Inc.'s:
Common stockholders' equity
19.6
%
9.6
%
16.9
%
5.4
%
Adjusted return on MetLife, Inc.'s:
Adjusted common stockholders' equity
15.4
%
13.8
%
15.2
%
13.6
%
Adjusted common stockholders' equity,
excluding total notable items
15.3
%
14.6
%
15.2
%
13.8
%
For the Three Months
Ended
For the Year Ended
December 31,
December 31,
Average Common Stockholders'
Equity
2024
2023
2024
2023
Average common stockholders' equity
$
25,347
$
24,019
$
25,008
$
25,784
Average adjusted common stockholders'
equity
$
37,867
$
39,368
$
38,084
$
40,599
Average adjusted common stockholders'
equity, excluding total notable items
$
37,846
$
39,392
$
38,076
$
40,608
See footnotes on last page.
MetLife, Inc.
Adjusted Earnings Available to
Common Shareholders
(In millions)
For the Three Months
Ended
For the Year Ended
December 31,
December 31,
2024
2023
2024
2023
Group Benefits (5):
Adjusted earnings available to common
shareholders
$
416
$
466
$
1,606
$
1,655
Less: Total notable items
—
—
(58
)
27
Adjusted earnings available to common
shareholders, excluding total notable items
$
416
$
466
$
1,664
$
1,628
Adjusted premiums, fees and other
revenues
$
6,184
$
6,001
$
24,870
$
23,929
Retirement & Income Solutions (5):
Adjusted earnings available to common
shareholders
$
386
$
421
$
1,667
$
1,708
Less: Total notable items
—
—
104
61
Adjusted earnings available to common
shareholders, excluding total notable items
$
386
$
421
$
1,563
$
1,647
Adjusted premiums, fees and other
revenues
$
3,620
$
2,883
$
8,594
$
8,832
Less: PRT
2,593
1,860
4,849
5,324
Adjusted premiums, fees and other
revenues, excluding PRT
$
1,027
$
1,023
$
3,745
$
3,508
Asia:
Adjusted earnings available to common
shareholders
$
443
$
296
$
1,621
$
1,282
Less: Total notable items
—
—
(41
)
(94
)
Adjusted earnings available to common
shareholders, excluding total notable items
$
443
$
296
$
1,662
$
1,376
Adjusted earnings available to common
shareholders on a constant currency basis
$
443
$
291
$
1,621
$
1,248
Adjusted earnings available to common
shareholders, excluding total notable items, on a constant currency
basis
$
443
$
291
$
1,662
$
1,342
Adjusted premiums, fees and other
revenues
$
1,635
$
1,705
$
6,757
$
6,969
Adjusted premiums, fees and other
revenues, on a constant currency basis
$
1,635
$
1,654
$
6,757
$
6,608
Latin America:
Adjusted earnings available to common
shareholders
$
201
$
207
$
881
$
840
Less: Total notable items
—
—
4
—
Adjusted earnings available to common
shareholders, excluding total notable items
$
201
$
207
$
877
$
840
Adjusted earnings available to common
shareholders on a constant currency basis
$
201
$
182
$
881
$
791
Adjusted earnings available to common
shareholders, excluding total notable items, on a constant currency
basis
$
201
$
182
$
877
$
791
Adjusted premiums, fees and other
revenues
$
1,438
$
1,486
$
5,936
$
5,727
Adjusted premiums, fees and other
revenues, on a constant currency basis
$
1,438
$
1,325
$
5,936
$
5,392
See footnotes on last page.
MetLife, Inc.
Adjusted Earnings Available to
Common Shareholders (Continued)
(In millions)
For the Three Months
Ended
For the Year Ended
December 31,
December 31,
2024
2023
2024
2023
EMEA:
Adjusted earnings available to common
shareholders
$
59
$
47
$
283
$
265
Less: Total notable items
—
—
(5
)
18
Adjusted earnings available to common
shareholders, excluding total notable items
$
59
$
47
$
288
$
247
Adjusted earnings available to common
shareholders on a constant currency basis
$
59
$
45
$
283
$
253
Adjusted earnings available to common
shareholders, excluding total notable items, on a constant currency
basis
$
59
$
45
$
288
$
235
Adjusted premiums, fees and other
revenues
$
652
$
595
$
2,548
$
2,346
Adjusted premiums, fees and other
revenues, on a constant currency basis
$
652
$
576
$
2,548
$
2,271
MetLife Holdings (5):
Adjusted earnings available to common
shareholders
$
153
$
156
$
647
$
733
Less: Total notable items
—
—
12
2
Adjusted earnings available to common
shareholders, excluding total notable items
$
153
$
156
$
635
$
731
Adjusted premiums, fees and other
revenues
$
815
$
901
$
3,272
$
3,708
Corporate & Other (5):
Adjusted earnings available to common
shareholders
$
(199
)
$
(232
)
$
(909
)
$
(958
)
Less: Total notable items
10
(76
)
10
(76
)
Adjusted earnings available to common
shareholders, excluding total notable items
$
(209
)
$
(156
)
$
(919
)
$
(882
)
Adjusted premiums, fees and other
revenues
$
93
$
100
$
402
$
455
See footnotes on last page.
MetLife, Inc.
For the Three Months
Ended
For the Year Ended
March 31, 2024
June 30, 2024
September 30, 2024
December 31, 2024
December 31,2024
Variable investment income
(post-tax, in millions) (6)
Group Benefits
$
4
$
3
$
2
$
1
$
10
RIS
73
64
50
71
258
Asia
56
99
44
121
320
Latin America
1
2
8
4
15
EMEA
—
—
—
—
—
MetLife Holdings
55
46
29
29
159
Corporate & Other
16
21
(5
)
6
38
Total variable investment income
$
205
$
235
$
128
$
232
$
800
Segments: Group Benefits, RIS,
Asia, Latin America and EMEA (7)
Capital Deployed
Value of New Business
Internal Rate of
Return
Payback (Years)
Value of new business ($ in
billions)
2023
$
3.6
$
2.6
19
%
5
2022
$
3.7
$
2.3
17
%
6
2021
$
2.8
$
1.9
17
%
6
2020
$
3.2
$
1.9
17
%
6
2019
$
3.8
$
1.8
15
%
7
Average asset balances (in
billions)
Private equity
$
14.3
Real estate and other funds
4.6
Total average asset balances
$
18.9
See footnotes on last page.
Condensed Reconciliation of
Net Cash Provided by Operating Activities of MetLife, Inc.
to Free Cash Flow of All
Holding Companies
(In billions, except
ratios)
For the Year Ended December
31,
2024
2023
MetLife, Inc. (parent company only) net
cash provided by operating activities
$
4.7
$
4.2
Adjustments from net cash provided by
operating activities to free cash flow:
Add: Incremental debt to be at or below
target leverage ratios
—
—
Add: Adjustments from net cash provided by
operating activities to free cash flow (8)
(0.1
)
(0.7
)
MetLife, Inc. (parent company only) free
cash flow
4.6
3.5
Other MetLife, Inc. holding companies free
cash flow (9)
—
0.1
Free cash flow of all holding
companies
$
4.6
$
3.6
Ratio of net cash provided by operating
activities to consolidated net income (loss) available to MetLife,
Inc.'s common shareholders:
MetLife, Inc. (parent company only) net
cash provided by operating activities
$
4.7
$
4.2
Consolidated net income (loss) available
to MetLife, Inc.'s common shareholders
$
4.2
$
1.4
Ratio of net cash provided by operating
activities (parent company only) to consolidated net income (loss)
available to MetLife, Inc.'s common shareholders (10)
112
%
303
%
Ratio of free cash flow to adjusted
earnings available to common shareholders:
Free cash flow of all holding companies
(11)
$
4.6
$
3.6
Consolidated adjusted earnings available
to common shareholders (11)
$
5.8
$
5.5
Ratio of free cash flow of all holding
companies to consolidated adjusted earnings available to common
shareholders (11)
79
%
66
%
See footnotes on last page.
MetLife, Inc.
December 31, 2024
Cash & Capital (12), (13), (14) (in
billions)
Holding Companies Cash & Liquid
Assets
$
5.1
Footnotes
(1)
Adjusted earnings available to common
shareholders, excluding total notable items, per diluted common
share is calculated on a standalone basis and may not equal (i)
adjusted earnings available to common shareholders per diluted
common share, less (ii) total notable items per diluted common
share.
(2)
Book values exclude $3,818 million of
equity related to preferred stock at both December 31, 2024 and
2023.
(3)
There were share repurchases of
approximately $0.4 billion and $3.2 billion for the three months
and year ended December 31, 2024, respectively. There were share
repurchases of approximately $470 million in January 2025.
(4)
Annualized using quarter-to-date
results.
(5)
Results on a constant currency basis are
not included as constant currency impact is not significant.
(6)
Assumes a 21% tax rate.
(7)
Excludes MetLife Holdings; Value of New
Business is the present value of future profits net of the cost of
capital and time value of guarantees from new sales.
(8)
Adjustments include: (i) capital
contributions to subsidiaries; (ii) returns of capital from
subsidiaries; (iii) repayments on and (issuances of) loans to
subsidiaries, net; and (iv) investment portfolio and derivatives
changes and other, net.
(9)
Components include: (i) dividends and
returns of capital from subsidiaries; (ii) capital contributions to
subsidiaries; (iii) repayments on and (issuances of) loans to
subsidiaries, net; (iv) other expenses; (v) dividends and returns
of capital to MetLife, Inc. and (vi) investment portfolio and
derivatives changes and other, net.
(10)
Including the free cash flow of other
MetLife, Inc. holding companies of $0 and $0.1 billion for the
years ended December 31, 2024 and 2023, respectively, in the
numerator of the ratio, this ratio, as adjusted, would be 112% and
311%, respectively.
(11)
i) Consolidated adjusted earnings
available to common shareholders for the year ended December 31,
2024, was positively impacted by notable items, primarily related
to tax adjustments of $0.1 billion, net of income tax, and
actuarial assumption review and other insurance adjustments of
$0.02 billion, net of income tax, offset by litigation reserves and
settlement costs of ($0.05) billion, net of income tax. Excluding
these notable items from the denominator of the ratio, the adjusted
free cash flow ratio for 2024, would be 79%.
ii) Consolidated adjusted earnings
available to common shareholders for the year ended December 31,
2023, was negatively impacted by notable items, related to
litigation reserves and settlement costs of ($0.1) billion, net of
income tax, offset by actuarial assumption review and other
insurance adjustments of $0.01 billion, net of income tax.
Excluding these notable items from the denominator of the ratio,
the adjusted free cash flow ratio for 2023, would be 65%.
(12)
The 2024 combined U.S. risk based capital
(RBC) ratio is estimated to be above MetLife's 360% target on an
NAIC basis. This ratio includes MetLife, Inc.'s principal U.S.
insurance subsidiaries, excluding American Life Insurance Company.
MetLife calculates RBC annually as of December 31 and, accordingly,
the calculation does not reflect conditions and factors occurring
after the year end.
(13)
The total U.S. statutory adjusted capital
is expected to be approximately $17.4 billion at December 31, 2024,
down 1% from September 30, 2024. This balance includes MetLife,
Inc.'s principal U.S. insurance subsidiaries, excluding American
Life Insurance Company.
(14)
The expected Japan solvency margin ratio
as of December 31, 2024 is approximately 675%.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250205240476/en/
For Media: Dave Franecki (973) 264-7465,
Dave.Franecki@metlife.com For Investors: John Hall (212) 578-7888,
John.A.Hall@metlife.com
MetLife (NYSE:MET)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
MetLife (NYSE:MET)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025